AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01625000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
Trial: NCT02082236
Drug: Treatment C: SSM 15 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 consecutive doses of SSM 15 mcg administered 20 minutes apart
Trial: NCT02082236
Drug: Treatment D: SSM 30 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 consecutive doses of SSM 30 mcg administered 1 hour apart
Trial: NCT01072877
Drug: Placebo Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vehicle
Trial: NCT01545570
Drug: GSK2376497
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2376497 Active Comparator
Trial: NCT01121120
Drug: TXA127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mcg/kg/day, administered subcutaneously for up to 28 days
Trial: NCT01121120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mcg/kg/day administered subcutaneously for up to 28 days
Trial: NCT02240641
Drug: Diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02240641
Drug: antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02240641
Drug: alpha blockers
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02240641
Drug: Angiotensin-Converting Enzyme Inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00699452
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02240641
Drug: beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00352885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
Trial: NCT03180970
Drug: 1.2% Lugol's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
Trial: NCT03180970
Drug: 1.0% Lugol's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
Trial: NCT03180970
Drug: 0.8% Lugol's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
Trial: NCT03180970
Drug: 0.6% Lugol's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
Trial: NCT03180970
Drug: 0.4% Lugol's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
Trial: NCT02658773
Drug: placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03282487
Drug: Modified release hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will switch from their usual conventional immediate release hydrocortisone to daily dose equivalent of modified release hydrocortisone (Plenadren®)
Trial: NCT01569048
Drug: propofol and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
Trial: NCT00002812
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00002812
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00002812
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00002812
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00656123
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2 administered IV on Day 1 of Cycles 1-4
Trial: NCT02685670
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01128946
Drug: NaF
RxNorm normalized name: Renaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
Trial: NCT01128946
Drug: SnF
RxNorm normalized name: Apex 26 Lead Trasnfer Set CS4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride toothpaste containing stannous fluoride (1100 ppmF)
Trial: NCT01128946
Drug: NaMFP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
Trial: NCT00145574
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Tablets
Trial: NCT01882530
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01339897
Drug: 5 mg/N6022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous formulation, given at doses of 5 mg once each day over 7 days.
Trial: NCT01339897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same administration procedures as active
Trial: NCT01339897
Drug: 10mg/N6022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous formulation given at doses of 10 mg once each day over 7 days.
Trial: NCT01339897
Drug: 20mg/N6022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous formulation given at doses of 20 mg once each day over 7 days.
Trial: NCT01884272
Drug: naproxen 250 mg
RxNorm normalized name: naproxen 250 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01884272
Drug: indomethacin 25 mg
RxNorm normalized name: indomethacin 25 MG
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03657095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, which are identical in size and appearance to those containing Esuberaprost.
Trial: NCT04202887
Drug: Low Dose Fentanyl
RxNorm normalized name: fentanyl Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml
Trial: NCT04202887
Drug: High Dose Fentanyl
RxNorm normalized name: fentanyl Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10ml bolus: bupivacaine 0.1% + 100mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 2mcg/ml
Trial: NCT00762658
Drug: AN2728 Ointment, 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00762658
Drug: AN2728 Ointment, 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00762658
Drug: AN2728 Ointment, 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00762658
Drug: AN2728 Ointment Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00762658
Drug: Betnesol®-V Creme, 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00762658
Drug: Protopic® Ointment, 0.1 %
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01438021
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intraventricularly
Trial: NCT01380834
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
Trial: NCT01380834
Drug: treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
Trial: NCT03214406
Drug: Arm & Hammer Advance White Brilliant Sparkle (Test product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% sodium bicarbonate
Trial: NCT00492336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet each day
Trial: NCT04103697
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/m2, bid, per os, days 1-14, 4 cycles
Trial: NCT04103697
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Trial: NCT00647751
Drug: Lamictal® Tablets 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x25mg, single dose fed
Trial: NCT02106520
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04623814
Drug: HEC113995
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days
Trial: NCT04623814
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administered fasted or with food for 10 days.
Trial: NCT04408261
Drug: Buqitongluo Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
Trial: NCT04408261
Drug: Buqitongluo Granule Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
Trial: NCT00647673
Drug: Verelan® PM Extended-Release Capsules 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg, single dose fasting
Trial: NCT00066027
Drug: 20 mg doxycycline hyclate
RxNorm normalized name: doxycycline hyclate 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years
Trial: NCT00066027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the placebo group took a placebo look-alike twice daily for two years.
Trial: NCT02680756
Drug: Ferric Carboxy Maltose
RxNorm normalized name: Maltose
DrugBank: Maltose (DB03323)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00182520
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 - 400 mg/day x 12 weeks
Trial: NCT04371718
Drug: JKB-122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JKB-122 is a TLR antagonist to immune modulate for autoimmune hepatitis
Trial: NCT00073970
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg, given twice daily
Trial: NCT03681691
Drug: Estradiol patch
RxNorm normalized name: Estradiol Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal 17β-estradiol patch
Trial: NCT00465985
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00465985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02752646
Drug: nepafenac 0.3%
RxNorm normalized name: NEPAFENAC 0.3% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.
Trial: NCT02752646
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.
Trial: NCT00662116
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets - two tablets taken twice daily
Trial: NCT00280033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo.
Trial: NCT03329443
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: each patient will receive 200 mg of spironolactone as per his/her angiography premedications
Trial: NCT03329443
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive a placebo tablet as per his/her angiography premedications
Trial: NCT00309556
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 cycles 1000mg/m2 oral, day 1-14 q2d
Trial: NCT03136263
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
Trial: NCT04674657
Drug: blood drug concentration
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blood drug concentration
Trial: NCT02221388
Drug: BI 671800 HEA, 200 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02221388
Drug: BI 671800 HEA EC, 200 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02221388
Drug: BI 671800 HEA, 50 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02221388
Drug: BI 671800 ED, 100 mg capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01280591
Drug: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
Trial: NCT01280591
Drug: Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
Trial: NCT01280591
Drug: Naproxen sodium 440 mg (BAYH6689)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received two Naproxen sodium 220 mg tablets orally, single dose
Trial: NCT01280591
Drug: DPH 50 mg
RxNorm normalized name: DPH 50 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
Trial: NCT02321306
Drug: LUM001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUM001 administered orally once each day.
Trial: NCT01996085
Drug: Indapamide/hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm)~2. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)
Trial: NCT01996085
Drug: Indapamide/hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug choice at the discretion of physician (blinded to ICG)
Trial: NCT02720406
Drug: saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% given by nebulizer before anesthesia and iv after anesthesia and before surgery.
Trial: NCT02454543
Drug: Best systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist.
Trial: NCT01971385
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01546688
Drug: Placebo administered to match targeted daily doses of 100-500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01178203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01178203
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab, 500 mg in 6, 12, and 24 hours after root canal treatment
Trial: NCT03120715
Drug: Low Molecular Weight Heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
Trial: NCT03543137
Drug: Nicorette Mini Lozenge
RxNorm normalized name: Nicorette Lozenge Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
Trial: NCT04027322
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for the control group.
Trial: NCT01928511
Drug: Nucleos(t)ide analogue therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00202956
Drug: Bugusan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00349778
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in \~250 mL of saline or D5W and infused IV over 2 hours
Trial: NCT02602054
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Indomethacin:~Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:~Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:~Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:~First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg~- Acetaminophen~Administer 1 full cycle, in the first fourteen days of life in preterm infants:~Acetaminophen 15 mg/kg every 6 hours for 3 days
Trial: NCT01821703
Drug: LY3045697
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as oral solution
Trial: NCT01821703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as oral solution
Trial: NCT01821703
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as capsule
Trial: NCT01821703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as capsule
Trial: NCT00881816
Drug: Liposomal paclitaxel plus capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
Trial: NCT02790684
Drug: DS-8500a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00367835
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00470925
Drug: 123-I MZINT injection and SPECT imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
Trial: NCT01372410
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mcg once daily
Trial: NCT01372410
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62.5 mcg once daily